Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Cubist, Morphosys and Takeda.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Feb 23, 2015

Sosei Acquires Heptares Therapeutics for up to USD 400 million

Jan 23, 2015

Heptares Scientists To Receive The Malcolm Campbell Memorial Prize For 2015 In Recognition Of Their Outstanding Contribution To GPCR Drug...


Apr 20-21, 2015
BPS: Exploiting the New Pharmacology and Application to Drug Discovery
Edinburgh, UK
Presenting: Fiona Marshall (CSO)

May 18-20, 2015
IBC’s 10th Annual Next Generation Protein Therapeutics Summit
San Francisco, CA, USA
Presenting: Cath Hutchings

© 2012-2015 Heptares Therapeutics